|
|
|
|
|
|
|
M Tue W Th F |
|
19 May, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
We have two dispatches from our summit last week with the Financial Times: Lydia Ramsey Pflanzer wrote about how pharma's embrace of direct-to-consumer channels is changing their relationship with patients. And I wrote about a question I keep getting: When will we get a Chinese big pharma company? |
|
|
|
Drew Armstrong |
Executive Editor, Endpoints News
@ArmstrongDrew
|
|
|
|
|
|
|
by Kyle LaHucik
|
The money continues to flow for drug development startups that are working on inflammatory and immunology medicines licensed from other companies. A new San Diego... | |
|
|
|
 |
|
Endpoints News Executive Editor Drew Armstrong leads a conversation on China biopharma at the Financial Times summit, with Susan Winckler, CEO of the Reagan-Udall Foundation for the FDA, and Caitlin Frazer, executive director of the National Security Commission on Emerging Biotechnology (courtesy of The Financial Times) |
|
|
|
by Drew Armstrong
|
Last week at our biopharma and healthcare summit with the Financial Times, I was asked during one of our breaks when we’ll see the... | |
|
|
|
 |
|
Endpoints News Deputy Editor Lydia Ramsey Pflanzer (R) speaks onstage at the US Pharma and Biotech Summit 2026 (Photographer: Viktoria Warpas) |
|
|
|
by Lydia Ramsey Pflanzer
|
Pharmaceutical companies’ ability to interact with the patients taking their medications has changed over the last few years. The rise of direct-to-consumer channels, driven largely... | |
|
|
|
|
|
|
by Kyle LaHucik
|
Parabilis Medicines, the decade-old and well-funded "undruggable" biotech out of Greg Verdine's Harvard lab, seeks to become the 12th drug developer to conduct an... | |
|
|
|
|
|
|
|
|
by Reynald Castaneda, Anna Brown
|
European healthcare investor GHO Capital and asset management firm CBC Group are set to join forces, with the new entity to manage over $21 billion... | |
|
|
|
|
|
